Massachusetts is currently home to 3361 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997
Recruiting
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Local Institution - 010, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
NCT04939597
Recruiting
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
05/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Central Nervous System Carcinoma
Register for Updates
A Study of NB003 in Patients With Advanced Malignancies
NCT04936178
Recruiting
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Solid Tumor
Register for Updates
Child and Adolescent Registry for Participants With Narcolepsy
NCT04899947
Recruiting
CATNAP is a patient registry designed to improve the understanding of the natural history of narcolepsy in pediatric patients. Descriptive statistics on disease characteristics will be performed. The study has 16 active clinical sites and a virtual site that widens participation to anywhere in the United States. For more information about the study or to access the Online Patient Enrollment System, visit the CATNAP website: https://catnap.healthie.net/welcome or email catnap@pulseinfoframe.com.... Read More
Gender:
All
Ages:
17 years and below
Trial Updated:
05/14/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Narcolepsy
Register for Updates
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
NCT04854096
Recruiting
This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count <50,000/µL) including subjects with intermediate-2 or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts
Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Register for Updates
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100
Recruiting
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study Comparing Two Types of Supportive Interventions for Caregivers of Patients With Cancer
NCT04802720
Recruiting
The purpose of this study is to compare two types of therapy for caregivers of cancer patients: Emotion Regulation Therapy for Cancer Caregivers (ERT-C) and Cognitive Behavioral Therapy (CBT-C). The researchers want to see if ERT-C is better than, the same as, or worse than traditional CBT-C at improving caregiver distress. The researchers will look at how the two types of therapy affect caregivers' anxiety, depression, and quality of life. The researchers will also see how ERT-C and CBT-C affec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cancer Patients, Family Caregivers
Register for Updates
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
NCT04796012
Recruiting
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Gender:
All
Ages:
Between 6 months and 18 years
Trial Updated:
05/14/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Solid Tumor, Rhabdomyosarcoma
Register for Updates
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586
Recruiting
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
05/14/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Primary Mediastinal Large B-Cell Lymphoma
Register for Updates
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368
Recruiting
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients... Read More
Gender:
All
Ages:
Between 3 years and 29 years
Trial Updated:
05/14/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Choriocarcinoma, Suprasellar Germ Cell Tumor
Register for Updates
AB154 Combined With AB122 for Recurrent Glioblastoma
NCT04656535
Recruiting
This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. The study will be divided into two cohorts: Cohort A (safety cohort) and Cohort B (surgical patient cohort). Cohort A: Eligible patients will be sequentially enrolled to receive intravenous AB154 combined with AB122 (N=6). AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat). Cohort B: Expansion surgical cohort. The purpose of cohort B is to pr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Glioblastoma
Register for Updates
Oxytocin for Weight Loss in Adolescents
NCT04551482
Recruiting
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 we... Read More
Gender:
All
Ages:
Between 12 years and 18 years
Trial Updated:
05/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Obesity, Adolescent, Oxytocin
Register for Updates